471 related articles for article (PubMed ID: 21756155)
1. Comparing treatment outcome of infliximab and adalimumab in patients with severe hidradenitis suppurativa.
van Rappard DC; Leenarts MF; Meijerink-van 't Oost L; Mekkes JR
J Dermatolog Treat; 2012 Aug; 23(4):284-9. PubMed ID: 21756155
[TBL] [Abstract][Full Text] [Related]
2. Long-term successful adalimumab therapy in severe hidradenitis suppurativa.
Blanco R; Martínez-Taboada VM; Villa I; González-Vela MC; Fernández-Llaca H; Agudo M; González-López MA
Arch Dermatol; 2009 May; 145(5):580-4. PubMed ID: 19451504
[TBL] [Abstract][Full Text] [Related]
3. Long-term efficacy of a single course of infliximab in hidradenitis suppurativa.
Mekkes JR; Bos JD
Br J Dermatol; 2008 Feb; 158(2):370-4. PubMed ID: 18047504
[TBL] [Abstract][Full Text] [Related]
4. Infliximab for severe hidradenitis suppurativa: transient clinical efficacy in 7 consecutive patients.
Fardet L; Dupuy A; Kerob D; Levy A; Allez M; Begon E; Bachelez H; Morel P; Lebbé C
J Am Acad Dermatol; 2007 Apr; 56(4):624-8. PubMed ID: 17240478
[TBL] [Abstract][Full Text] [Related]
5. A double-blind placebo-controlled randomized trial of adalimumab in the treatment of hidradenitis suppurativa.
Miller I; Lynggaard CD; Lophaven S; Zachariae C; Dufour DN; Jemec GB
Br J Dermatol; 2011 Aug; 165(2):391-8. PubMed ID: 21457202
[TBL] [Abstract][Full Text] [Related]
6. A prospective open-label clinical trial of efficacy of the every week administration of adalimumab in the treatment of hidradenitis suppurativa.
Sotiriou E; Goussi C; Lallas A; Chovarda E; Apalla Z; Lazaridou E; Ioannides D
J Drugs Dermatol; 2012 May; 11(5 Suppl):s15-20. PubMed ID: 22644772
[TBL] [Abstract][Full Text] [Related]
7. A prospective open-label clinical trial of adalimumab for the treatment of hidradenitis suppurativa.
Amano M; Grant A; Kerdel FA
Int J Dermatol; 2010 Aug; 49(8):950-5. PubMed ID: 21128923
[TBL] [Abstract][Full Text] [Related]
8. Effective long-term control of refractory hidradenitis suppurativa with adalimumab after failure of conventional therapy.
Arenbergerova M; Gkalpakiotis S; Arenberger P
Int J Dermatol; 2010 Dec; 49(12):1445-9. PubMed ID: 21091684
[TBL] [Abstract][Full Text] [Related]
9. Adalimumab for the treatment of moderate to severe Hidradenitis suppurativa: a parallel randomized trial.
Kimball AB; Kerdel F; Adams D; Mrowietz U; Gelfand JM; Gniadecki R; Prens EP; Schlessinger J; Zouboulis CC; van der Zee HH; Rosenfeld M; Mulani P; Gu Y; Paulson S; Okun M; Jemec GB
Ann Intern Med; 2012 Dec; 157(12):846-55. PubMed ID: 23247938
[TBL] [Abstract][Full Text] [Related]
10. Treatment of severe recalcitrant hidradenitis suppurativa with adalimumab.
Harde V; Mrowietz U
J Dtsch Dermatol Ges; 2009 Feb; 7(2):139-41. PubMed ID: 19371236
[TBL] [Abstract][Full Text] [Related]
11. Infliximab for the treatment of hidradenitis suppurativa.
Fernández-Vozmediano JM; Armario-Hita JC
Dermatology; 2007; 215(1):41-4. PubMed ID: 17587838
[TBL] [Abstract][Full Text] [Related]
12. Hidradenitis suppurativa responding to treatment with infliximab.
Lasocki A; Sinclair R; Foley P; Saunders H
Australas J Dermatol; 2010 Aug; 51(3):186-90. PubMed ID: 20695857
[TBL] [Abstract][Full Text] [Related]
13. Etanercept: effective in the management of hidradenitis suppurativa.
Cusack C; Buckley C
Br J Dermatol; 2006 Apr; 154(4):726-9. PubMed ID: 16536817
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of infliximab for hidradenitis suppurativa: assessment of clinical and biological inflammatory markers.
Delage M; Samimi M; Atlan M; Machet L; Lorette G; Maruani A
Acta Derm Venereol; 2011 Mar; 91(2):169-71. PubMed ID: 21384087
[TBL] [Abstract][Full Text] [Related]
15. Adalimumab (antitumour necrosis factor-α) treatment of hidradenitis suppurativa ameliorates skin inflammation: an in situ and ex vivo study.
van der Zee HH; Laman JD; de Ruiter L; Dik WA; Prens EP
Br J Dermatol; 2012 Feb; 166(2):298-305. PubMed ID: 22013960
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and tolerance of prolonged infliximab treatment of moderate-to-severe forms of hidradenitis suppurativa.
Lesage C; Adnot-Desanlis L; Perceau G; Bonnet M; Palot JP; Bernard P; Reguiaï Z
Eur J Dermatol; 2012; 22(5):640-4. PubMed ID: 22759562
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of adalimumab in the treatment of psoriasis: a retrospective study of 15 patients in daily practice.
Sola-Ortigosa J; Sánchez-Regaña M; Umbert-Millet P
J Dermatolog Treat; 2012 Jun; 23(3):203-7. PubMed ID: 21787203
[TBL] [Abstract][Full Text] [Related]
18. Experience with ustekinumab for the treatment of moderate to severe hidradenitis suppurativa.
Gulliver WP; Jemec GB; Baker KA
J Eur Acad Dermatol Venereol; 2012 Jul; 26(7):911-4. PubMed ID: 21605174
[TBL] [Abstract][Full Text] [Related]
19. Assessing the validity, responsiveness and meaningfulness of the Hidradenitis Suppurativa Clinical Response (HiSCR) as the clinical endpoint for hidradenitis suppurativa treatment.
Kimball AB; Jemec GB; Yang M; Kageleiry A; Signorovitch JE; Okun MM; Gu Y; Wang K; Mulani P; Sundaram M
Br J Dermatol; 2014 Dec; 171(6):1434-42. PubMed ID: 25040429
[TBL] [Abstract][Full Text] [Related]
20. Long-term efficacy of infliximab in hidradenitis suppurativa.
Paradela S; Rodríguez-Lojo R; Fernández-Torres R; Arévalo P; Fonseca E
J Dermatolog Treat; 2012 Aug; 23(4):278-83. PubMed ID: 22482700
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
